MAIA Biotechnology Inc. (MAIA)

AI Score

Unlock

1.55

0.01 (0.65%)

At close: Apr 17, 2025, 3:58 PM

0.65% (1D)

Bid	1.53
Market Cap	45.86M
Revenue (ttm)	n/a
Net Income (ttm)	-23.25M
EPS (ttm)	-1.05
PE Ratio (ttm)	-1.48
Forward PE	-2.3
Analyst	n/a

Ask	1.6
Volume	36,734
Avg. Volume (20D)	197,732
Open	1.56
Previous Close	1.54
Day's Range	1.51 - 1.59
52-Week Range	1.40 - 5.99
Beta	0.39

About MAIA

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois....

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 28, 2022

Employees 13

Stock Exchange AMEX

Ticker Symbol MAIA

Website https://www.MAIABiotech.com

Full Company Profile

Why Price Moved

1 month ago

-1.07%

MAIA Biotechnology shares are trading lower after ... Unlock content with Pro Subscription

2 months ago

+5.82%

MAIA Biotechnology shares are trading higher after the company announced updated data from its THIO-101 Phase 2 clinical trial evaluating THIO.

News

2 weeks ago · businesswire.com

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders.

3 weeks ago · zacks.com

MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know

MAIA Biotechnology, Inc. (MAIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago · businesswire.com

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025.

4 weeks ago · businesswire.com

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug.

4 weeks ago · businesswire.com

MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO.

1 month ago · businesswire.com

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

CHICAGO--(BUSINESS WIRE)--MAIA to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced NSCLC Patients.